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Background: The role of mitochondrial dysfunction has long been implicated in age-related brain pathology, including
Alzheimer’s disease (AD). However, the mechanism by which mitochondrial dysfunction may cause neurodegeneration
in AD is unclear. To model mitochondrial dysfunction in vivo, we utilized mice that harbor a knockin mutation that
inactivates the proofreading function of mitochondrial DNA polymerase γ (PolgA D257A), so that these mice accumulate
mitochondrial DNA mutations with age. PolgA D257A mice develop a myriad of mitochondrial bioenergetic defects and
physical phenotypes that mimic premature ageing, with subsequent death around one year of age.
Results: We crossed the D257A mice with a well-established transgenic AD mouse model (APP/Ld) that develops amyloid
plaques. We hypothesized that mitochondrial dysfunction would affect Aβ synthesis and/or clearance, thus contributing
to amyloidogenesis and triggering neurodegeneration. Initially, we discovered that Aβ42 levels along with Aβ42 plaque
density were increased in D257A; APP/Ld bigenic mice compared to APP/Ld monogenic mice. Elevated Aβ production
was not responsible for increased amyloid pathology, as levels of BACE1, PS1, C99, and C83 were unchanged in D257A;
APP/Ld compared to APP/Ld mice. However, the levels of a major Aβ clearance enzyme, insulin degrading enzyme (IDE),
were reduced in mice with the D257A mutation, suggesting this as mechanism for increased amyloid load. In
the presence of the APP transgene, D257A mice also exhibited significant brain atrophy with apparent cortical
thinning but no frank neuron loss. D257A; APP/Ld mice had increased levels of 17 kDa cleaved caspase-3 and
p25, both indicative of neurodegeneration. Moreover, D257A; APP/Ld neurons appeared morphologically disrupted,
with swollen and vacuolated nuclei.
Conclusions: Overall, our results implicate synergism between the effects of the PolgA D257A mutation and Aβ in
causing neurodegeneration. These findings provide insight into mechanisms of mitochondrial dysfunction that may
contribute to the pathogenesis of AD via decreased clearance of Aβ.
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Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder that is the most common cause of dementia in the
elderly [1-3]. A major neuropathological feature of AD is
the presence of neuritic plaques that are primarily com-
posed of the 42-amino acid β-amyloid (Aβ) peptide, Aβ42.
Aβ peptides are endoproteolytically processed from the
amyloid-β precursor protein (APP) via sequential cleavages
enacted by BACE1 (β-secretase) and γ-secretase [4]. Most
of the genetic factors known to increase susceptibility to
Alzheimer’s disease increase the levels of Aβ in the brain
(reviewed in [3]). Though numerous studies have shown
that cerebral accumulation of Aβ plays a critical early role
in AD pathogenesis, the underlying mechanism by which
Aβ causes neurodegeneration remains unclear.
Mitochondrial dysfunction has been implicated in age-
related cognitive decline (reviewed in [5]) and potentially
plays a central role in the progression of Alzheimer’s dis-
ease. Pyramidal neurons, which require large amounts of
cellular energy, are the most vulnerable to mitochondrial
dysfunction [6]. Compared to age-matched controls, AD
patients have significantly higher levels of mitochondrial
DNA (mtDNA) deletions in large vulnerable neurons of the
hippocampus and neocortex [7,8]. Interestingly, Down syn-
drome patients with AD dementia also have an increase in
mtDNA mutations [9]. Aside from changes in mtDNA, AD
mitochondria have decreased electron transport chain com-
plex (ETC) IV, morphological changes in cristae, accumula-
tion of osmiophilic material and decreased size [8,10].
There is evidence that Aβ-mediated toxicity may
cause morphological, chemical and genetic changes in
mitochondria. In vitro studies show that the accumula-
tion of Aβ impairs mitochondrial biogenesis, dynamics
and axonal transport [11-13]. Aβ also promotes oxidative
stress, which can consequently introduce mutations in
mtDNA and impair mitochondrial function [14-16]. In an
in vivo study, severe toxicity was induced in the immediate
vicinity of amyloid plaques, causing structural and func-
tional abnormalities in mitochondria [17].
In our study, we sought to determine how Aβ mediated
toxicity and Aβ pathology interacts with mitochondrial
dysfunction in vivo. We modeled mitochondrial dysfunc-
tion in vivo by utilizing a mouse that contains a knockin
mutation that inactivates the proofreading function of
mitochondrial DNA polymerase-γ (PolgA D257A) [18].
The proofreading activity of mitochondrial DNA
polymerase-γ has been shown both in mice and human
cells to be critical for preventing accumulation of
mtDNA mutations with age (reviewed in [19]). In
humans, mutations in the PolgA gene cause various
central nervous system disorders including cognitive
decline [20]. In PolgA D257A mice, previous reports
show that the animals rapidly develop a myriad of
mitochondrial bioenergetic defects in multiple tissues,including the brain, and physical phenotypes that
mimic premature ageing, including increased mortality
after 1 year of age [18,21-23].
We crossed the PolgA D257A mice with a well-
established transgenic AD mouse model carrying the
APP familial London mutation (APPV717I; APP/Ld).
APP/Ld mice do not exhibit neuron loss but develop
amyloid plaques at ~1 year of age [24]. Since age is the
greatest risk factor in Alzheimer’s disease and PolgA
D257A mice exhibit a premature aging phenotype, we
investigated whether PolgA D257A; APP/Ld bigenic
mice may model the interaction between mitochon-
drial dysfunction associated with aging and Aβ toxicity
in the onset and progression of AD. We hypothesized
that mitochondrial dysfunction may affect the balance
between Aβ synthesis and clearance, thus contributing
to amyloidogenesis and potentially triggering neurode-
generation. Here, we provide evidence that the PolgA
D257A mutation may increase β-amyloid accumulation by
reducing IDE levels and thus impairing Aβ-clearance. In
contrast, levels of the Aβ-generating enzymes BACE1 and
PS1 or the APP C-terminal fragments (CTFs) C99 and C83
do not change in the presence of the PolgA D257A muta-
tion. We also provide morphological and biochemical evi-
dence of neurodegeneration in mice expressing the PolgA
D257A mutation and APP/Ld transgene characterized by
cortical and hippocampal atrophy and neuronal swelling
and vacuolization. Our results suggest synergism between
mitochondrial dysfunction and cerebral Aβ accumulation
in some aspects of brain atrophy and neurodegeneration.
These findings lend insights into the roles of mitochondrial
dysfunction, amyloid pathology, and - more broadly - age-
ing in AD pathogenesis.
Results
Homozygous PolgA D257A mutation increases amyloid
load in APP/Ld mice
Aging is the primary risk factor for AD, yet little is
known regarding the mechanism of aging that drives AD
pathogenesis. To model the effects that age-associated
mitochondrial dysfunction may have on the develop-
ment of amyloid pathology, we crossed PolgAD257A/D257A
mitochondrial DNA mutator mice (D257A mice; [18])
with transgenic mice that overexpress human APP har-
boring the London (V717I) familial AD (FAD) mutation
(APP/Ld mice; [24]). We chose the APP/Ld mouse
model because the transgenic APP sequence is wild-type
at the BACE1 cleavage site, which allowed us to investigate
the effects of mitochondrial mutations on BACE1 process-
ing of APP in the absence of the BACE1-preferred APP
Swedish mutation that may mask the effects of subtle
changes in rates of BACE1 cleavage. This wild type APP
BACE1 cleavage site more closely mimics BACE1 process-
ing in sporadic AD. APP/Ld mice begin depositing amyloid
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and bigenic offspring of the above cross to ~12 months
and analyzed the following 4 genotypes: 1) homozygous
D257A; hemizygous APP/Ld, 2) homozygous D257A, 3)
hemizygous APP/Ld, 4) wild-type.
First, we determined whether the D257A mutation
could increase cerebral levels of the toxic fibrillogenic
42-amino-acid isoform of Aβ (Aβ42) that accumulates in
amyloid plaques and is associated with FAD. Whole brain
homogenates from 12 month-old D257A; APP/Ld bigenic
and APP/Ld mice were analyzed using a human Aβ42-
specific ELISA (Figure 1A). Interestingly, D257A; APP/Ld
mice exhibited a trend toward higher Aβ42 levels comparedFigure 1 PolgA D257A mutation increases normalized Aβ42 levels in
and D257A; APP/Ld mice were prepared and Aβ42 levels were measured u
per milligram of total brain protein. Note that the raw Aβ42 levels are not
upward trend exists, as compared to APP/Ld mice (n = 12). (B) 15 μg/lane of t
analysis of full-length transgenic human APP/Ld protein using the anti-human A
control. The numbers on immunoblot correspond to specific genotypes (as den
randomly loaded. (C) Full-length APP/Ld immunosignals in (B) were quantified
and expressed as percentage of the mean APP/Ld immunosignal. Note th
mice compared to APP/Ld mice (mean ± SEM; **p < 0.01; Student’s t-test).
mean transgenic APP/Ld protein levels for each genotype as determined
increased in the D257A; APP/Ld mice compared to APP/Ld mice (mean ±to age-matched APP/Ld littermate mice (p = 0.2585). One
possible explanation of this upward Aβ42 trend could in-
volve increased expression of the APP transgene in D257A;
APP/Ld mice. To test this hypothesis, we performed
immunoblot analysis of whole brain homogenates using the
anti-human APP antibody 6E10 (Figure 1B,C). Unexpect-
edly, we observed that transgenic human APP levels in
D257A; APP/Ld mice were only ~60% of those exhibited
in APP/Ld mice. In contrast, endogenous mouse APP
levels were unaffected by the presence of homozygous
PolgAD257A/D257A in D257A mice compared to wild-type
littermates (Additional file 1: Figure S1A,B). The mechan-
ism by which the D257A mutation reduces transgenicAPP/Ld mice. (A) Hemi-brain homogenates of ~12 month-old APP/Ld
sing a human Aβ42-specific ELISA. Values are expressed in nanograms
significantly elevated in D257A; APP/Ld mice (n = 10), but that an
he same mouse brain homogenates in (A) were used for immunoblot
PP monoclonal antibody 6E10. Ponceau S staining was used as a loading
oted in boxed legend key) of individual brain homogenates that were
by phosphorimager, normalized to Ponceau S staining intensities per lane,
at levels of APP/Ld are significantly reduced in the D257A; APP/Ld
(D) Raw Aβ42 ELISA values (ng/mg) from (A) were normalized to the
in (C). Note that Aβ42 levels normalized to APP/Ld are significantly
SEM; *p < 0.05; Student’s t-test).
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may relate to a neurodegenerative process driven by a syn-
ergistic interaction between the effects of Aβ and those of
the D257A mutation (see below). Most importantly, the
D257A mutation resulted in a statistically significant ~2-
fold increase in Aβ42 level when normalized to transgenic
APP level in D257A; APP/Ld mice as compared to APP/Ld
mice (Figure 1D). In other words, twice as much Aβ42 pep-
tides per given amount of transgenic APP protein had accu-
mulated in the brains of D257A; APP/Ld bigenic mice than
in APP/Ld monogenic mice.
Next, we determined whether the ~2-fold elevation
in normalized Aβ42 level caused by the D257A muta-
tion translated into increased amyloid plaque number
in D257A; APP/Ld transgenic mice. Coronal brain sec-
tions from the same 12 month-old mice as above were
co-stained with thiazine red (for β-sheet amyloid) and
anti-Aβ42-selective antibody, imaged by fluorescence
microscopy and counted for Aβ42-positive plaques
(Figure 2). Diffuse and dense-core plaques were rela-
tively small in size and sparsely distributed throughout
the cortex and hippocampus of D257A; APP/Ld and
APP/Ld mice (Figure 2A), as expected for this rela-
tively early stage of plaque formation in this AD mouse
model. Interestingly, plaques were observed in the
thalamus of D257A; APP/Ld mice, but were largely ab-
sent in the thalamus of APP/Ld mice. D257A; APP/Ld
mice exhibited a trend toward higher amyloid plaque
density, expressed as Aβ42-positive plaques per total
area analyzed, compared to age-matched APP/Ld lit-
termate mice (p = 0.2109) (Figure 2B). As with normal-
ized Aβ42 levels by ELISA (Figure 1D), the plaque
densities normalized to transgenic APP levels were sig-
nificantly increased by over 2-fold in D257A; APP/Ld
mice compared to APP/Ld mice (p < 0.05) (Figure 2C).
Moreover, amyloid plaque size appeared to be larger
on average in D257A; APP/Ld brains relative to APP/
Ld (Figure 2A right, insets outlined in red). Thus,
homozygous D257A mutation led to greater amyloid
plaque loads in the brains of APP/Ld transgenic mice.
Homozygous PolgA D257A mutation prevents APP/Ld
transgene-induced IDE elevation but does not affect
levels of NEP or Aβ generating enzymes in APP/Ld mice
In principle, the elevation of normalized amyloid load in
D257A; APP/Ld mice could have resulted from either an
increase in Aβ production or a decrease in Aβ clearance
and/or degradation. To address the question of increased
Aβ production first, we measured the levels of Aβ generat-
ing enzymes BACE1 and presenilin 1 (PS1) by immunoblot
analysis on whole brain homogenates of 12 month-old
D257A; APP/Ld, APP/Ld, D257A, and wild-type mice
(Figure 3). BACE1 is the key enzyme that initiates the
production of Aβ [25-31]. Consistent with our previousanalyses of other APP transgenic mice [32-34], mice ex-
pressing the human APP/Ld transgene exhibited increased
cerebral levels of BACE1 protein compared to wild-type
non-transgenic control mice (Figure 3A,B). D257A; APP/
Ld bigenic mice also displayed increased BACE1 levels, but
homozygous D257A mutation did not enhance the APP
transgene-induced BACE1 elevation. Mice harboring the
D257A mutation alone showed similar BACE1 levels as
wild-type controls. To investigate whether the D257A mu-
tation may have enhanced BACE1 activity independent of
BACE1 level, we analyzed the levels of the BACE1-cleaved
C99 APP CTF and the α-secretase processed CTF, C83
(Figure 3C). Since BACE1 and α-secretase compete to
cleave APP under some circumstances [25], an increase in
the C99:C83 ratio may indicate a shift towards higher
BACE1 activity. However, we observed no difference in the
C99:C83 ratio between D257A; APP/Ld and APP/Ld mice
(Figure 3D). Additionally, the individual levels of C83 and
C99 did not change in D257A; APP/Ld mice as compared
to APP/Ld mice, suggesting that the D257A mutation
does not alter activities of either α- or β-secretase
independently (Figure 3E,F). Finally, we examined
whether PS1/γ-secretase levels were changed in the
presence of the D257A mutation by performing immu-
noblot analysis for PS1 N-terminal fragment (NTF)
(Figure 3G,H). Presenilin is the catalytic subunit of the
γ-secretase complex that, in addition to BACE1, is also
required for Aβ generation. No changes in PS1 NTF
levels were observed in the brains of mice regardless of
genotype. Taken together, these findings indicate that
homozygous D257A mutation did not significantly
affect the protein and activity levels of Aβ generating
enzymes in the brains of transgenic mice, suggesting
that that elevation of the normalized Aβ42 level and
amyloid plaque load observed in D257A; APP/Ld mice
was unlikely the result of increased Aβ production.
Next, we explored the possibility that cerebral amyl-
oid accumulation in D257A; APP/Ld mice could be
due to impaired Aβ degradation. Insulin degrading
enzyme (IDE) and neprilysin (NEP) are major Aβ de-
grading enzymes in the brain [35-37]. It has been pre-
viously reported that IDE levels become elevated in
response to Aβ [38,39], suggesting a feedback mechan-
ism of IDE regulation for lowering cerebral Aβ levels.
We performed immunoblot analysis for IDE and NEP
levels in whole brain homogenates from 12 month-old
D257A; APP/Ld, APP/Ld, D257A, and wild-type mice
(Figure 4). Consistent with previous reports [38,39], IDE
levels were significantly elevated in response to Aβ accumu-
lation in the brains of APP/Ld compared to wild-type mice
(Figure 4A,B). We also observed a small but significant de-
crease of IDE level in D257A mice relative to wild-type. Im-
portantly, the Aβ-induced IDE increase was completely
abrogated by the presence of homozygous D257A
Figure 2 PolgA D257A mutation increases amyloid plaque pathology in APP/Ld mouse brains. (A) Hemi-brains of the same mice from Figure 1
were fixed, sectioned coronally, and co-stained with anti-Aβ42 specific antibody (green) and thiazine red for β-sheet amyloid and imaged by
immunofluorescence microscopy. (A) Representative coronal brain sections of APP/Ld (left) and D257A; APP/Ld mice (right). Both APP/Ld and
D257A; APP/Ld mice exhibit diffuse (green box) and dense-core (red box) plaques. The insets show high-magnification images of plaques in
green and red boxes. Dense-core plaques are positive for both Aβ42 and thiazine red, while diffuse plaques are only Aβ42-immunopositive. In
addition to the cortex, D257A; APP/Ld mice form plaques in other brain regions such as the thalamus (for example see red arrow) Blue = DAPI.
Scale bar: 500 μm (25 μm in insets). (B) The amyloid plaque density (number of Aβ42-positive plaques per cm2) was determined from representative brain
sections with equivalent rostral-caudal location from D257A; APP/Ld (n = 10) and APP/Ld (n = 12) mice. (C) Plaque densities in (B) were normalized to
human transgenic APP protein levels as determined by APP immunoblot analysis (Figure 1C). Note that normalized Aβ42 plaque density is significantly
increased in D257A; APP/Ld mice compared to APP/Ld mice (mean ± SEM; *p < 0.05; Student’s t-test).
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NEP levels were unchanged regardless of genotype in
the brains of transgenic mice (Figure 4C,D). Together,
these results suggest the intriguing possibility that the
elevated Aβ42 level and amyloid plaque load in D257A;
APP/Ld bigenic mice is the result of D257A-associated
inhibition of the Aβ-induced IDE increase, thus leading
to reduced IDE-mediated degradation of Aβ.Homozygous PolgA D257A mutation and APP/Ld
transgene expression synergize to cause brain atrophy
and neurodegeneration
Unlike in AD patients, the brains of most lines of APP
transgenic mice do not exhibit significant brain atro-
phy. However, during the course of our study, we no-
ticed that the brains of 12 month-old D257A; APP/Ld
mice appeared smaller compared to brains of the other
Figure 3 (See legend on next page.)
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Figure 4 PolgA D257A mutation prevents Aβ-induced IDE elevation. Brain homogenates were prepared from D257A; APP/Ld, D257A, APP/
Ld, and wild type mice and 10 μg protein/lane was randomly loaded and subjected to immunoblot analysis for two Aβ degrading enzymes:
insulin degrading enzyme (IDE) and neprilysin (NEP). Immunoblot signals were normalized to Ponceau S staining intensities in a given lane.
The numbers on immunoblot correspond to a mouse with a specific genotype as denoted in the legend key (box). (A) IDE protein from brain
homogenates runs at ~100 kDa. (B) IDE immunosignals from (A) were measured and expressed as percentage of mean wild-type IDE level. Note
that IDE levels are reduced slightly in the brains of D257A mice. As previously reported for APP transgenic mice [38,39], IDE levels are significantly
increased in the brains of APP/Ld mice compared to wild-type non-transgenic mice. Most importantly, the D257A mutation completely prevents
the Aβ-induced increase in IDE levels in D257A; APP/Ld mice (mean ± SEM; n.s. = not significant; *p < 0.05; ***p < 0.001; One-way ANOVA followed
by Newman–Keuls multiple-comparisons post hoc test). (C) NEP protein from brain homogenates runs at ~90 kDa. (D) NEP immunosignals from
(C) were measured and expressed as percentage of mean wild-type NEP level. Note that NEP levels are not altered by the D257A mutation, the
APP/Ld transgene, or their combination, as compared to wild-type non-transgenic mice.
(See figure on previous page.)
Figure 3 PolgA D257A mutation does not affect levels of Aβ generating enzymes in APP/Ld mice. 15 μg of brain homogenates from
D257A; APP/Ld, D257A, APP/Ld, and wild type mice were loaded per lane and subjected to immunoblot analysis. Immunoblot signals were
normalized to the Ponceau S staining intensity for a given lane. The numbers on the immunoblot correspond to mice with specific genotypes as
denoted in the legend key (box). (A) BACE1 protein runs at ~68 kDa. (B) BACE1 immunosignals in (A) were expressed as the percentage of the
mean wild-type mouse BACE1 immunosignal. Note that BACE1 levels are significantly higher in APP/Ld monogenic and D257A; APP/Ld bigenic
mice compared to D257A and wild type non-transgenic mice. BACE1 levels are not altered by the presence of the D257A mutation (mean ±
SEM; **p < 0.01; ***p < 0.001; One-way ANOVA followed by Newman–Keuls multiple-comparisons post hoc test). (C) APP processing was
determined by measuring levels of both APP C-terminal fragments (C83 & C99) via immunoblot using a rabbit monoclonal antibody that
recognizes the C-terminus of APP. Note however, that these C-terminal fragments were below the level of immunoblot detection in non-transgenic APP
mouse brains. (D) The ratio of C99:C83, which is directly proportional to the fraction of APP cleaved by BACE1, is not altered by the presence of the D257A
mutation. Separate quantification of C83 (E) and C99 (F), normalized to Ponceau S, also show that α- and β-secretase activities are not altered
independently of one another by the D257A mutation. (G) PS1 protein levels were measured by immunoblot analysis using a PS1 N-terminal
antibody. (H) PS1 immunosignals in (G) were expressed as the percentage of the mean wild-type control PS1 level. PS1-NTF levels are not altered in the
presence of the D257A mutation or the APP/Ld transgene.
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further, we performed hematoxylin staining on coronal
brain sections and found that significant shrinkage of the
brain had occurred only in the combined presence of the
homozygous D257A mutation and the APP/Ld transgene
(Figure 5A). Analysis of the cortex and hippocampus re-
vealed that D257A; APP/Ld mice exhibited ~70% and ~80%
of the lateral cortical thickness and hippocampal area ofFigure 5 Co-expression of the PolgA D257A mutation and APP/Ld tra
from D257A; APP/Ld, D257A, APP/Ld, and wild type mice were selected
imaged by light microscopy. Mouse genotypes are indicated above the
to the hippocampus (boxed areas) are presented to the right of each lo
are significantly smaller in size compared to the other genotypes. Espec
mice. (scale bar = 250 μm for high magnification, 2 mm for low magnific
length of a line (drawn in the wild-type high magnification image in (A)
of the CA1 region of the hippocampus to the visible boundary of the co
of the cortex compared to the other genotypes (n = 5; mean ± SEM; *p < 0.05; O
hoc test). (C) Hippocampal area (μm2) of the different genotypes was also
reduced hippocampal area compared to APP/Ld, D257A or wild-type mi
followed by Newman–Keuls multiple-comparisons post hoc test).mice of the other genotypes, respectively (Figure 5B,C).
These results demonstrate the presence of significant
brain atrophy only in the D257A; APP/Ld mice, suggest-
ing synergism between the effects of homozygous PolgA
D257A mutation and APP/Ld transgene expression lead-
ing to reduced brain size.
While examining hematoxylin stained sections, we ob-
served that many cortical and hippocampal neurons ofnsgene causes brain atrophy. (A) Coronal sections (30 μm) of brains
from similar rostral-caudal positions, stained with hematoxylin and
micrographs. High magnification images of cortical regions dorsal
w magnification image. Note that the brains of D257A; APP/Ld mice
ially noticeable is the reduced cortical thickness of D257A; APP/Ld
ation). (B) Lateral cortical thickness (μm) was measured as the
) running perpendicular to the cortical layers from the dorsal edge
rtex. The brains of D257A; APP/Ld mice show significant thinning
ne-way ANOVA followed by Newman–Keuls multiple-comparisons post
measured. Note that D257A; APP/Ld mice also exhibit significantly
ce (n = 5; mean ± SEM; **p < 0.01; ***p < 0.001; One-way ANOVA
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features suggestive of apoptosis, including clear cyto-
plasm and swollen deformed vacuolated nuclei with
marginated chromatin (Figure 6). These neuronal phe-
notypes were very rare or absent in neurons of APP/Ld,
D257A, or wild-type mice. Interestingly, a variety of
histopathological studies have documented similar mor-
phological features of apoptosis in neurons of AD brains
(reviewed in [40]).
Caspase activation, a biochemical marker of apoptosis,
has been reported in AD [41,42] and in different lines of
APP transgenic mice [43-46]. To investigate whether
apoptosis might be associated with the brain atrophy ob-
served in D257A; APP/Ld mice, we measured levels of
the cleaved 17 kDa fragment of caspase-3 as a marker of
capase-3 activation. Immunoblot analysis of whole brain
homogenates with an antibody that recognizes the neoe-
pitope of 17 kDa cleaved caspase-3 showed that cleaved
caspase-3 levels were nearly 50% higher in the brains of
12 month D257A; APP/Ld mice than in wild-type or
D257A mice (Figure 7A,B). As expected, cleaved caspase-3
levels were also elevated in brains of APP/Ld mice, but to a
lesser extent than in D257A; APP/Ld mice. In addition, we
immunostained coronal brain sections with the cleavedFigure 6 Co-expression of the PolgA D257A mutation and APP/Ld tra
Coronal sections (30 μm) of brains from D257A; APP/Ld, D257A, APP/Ld, an
stained with hematoxylin, and cortical layer V neurons imaged at high mag
each column. Representative brain sections from four different mice from e
APP/Ld neurons have abnormal morphologies and display vacuolated nucl
features are absent in neurons in D257A, APP/Ld and wild-type brains (scalcaspase-3 neoepitope antibody and observed cleaved
caspase-3 positive puncta in the cortex of D257A;
APP/Ld and APP/Ld mice, but not in wild-type or
D257A mice (Figure 7C). These caspase-3 positive
puncta appeared similar in size, shape and distribution
as those reported in the brains of other APP transgenic
mice [43,46]. Together, these results suggest that the
D257A mutation exacerbates APP/Ld transgene-associated
activation of caspase-3 in neurons of the brain, thus pro-
moting apoptosis.
The calpain-cleaved fragment of the p35 regulator of
Cdk5, termed p25, is associated with neurodegeneration
in humans and animal models (reviewed in [47]). To de-
termine whether p25 levels were elevated in the pres-
ence of the D257A mutation, we performed immunoblot
analysis of whole brain homogenates with an antibody
that recognizes both p35 and p25 (Figure 7D,E). Similar
in magnitude to the increase in cleaved caspase-3 level, the
p25:p35 ratio was ~50% higher in the brains of 12 month-
old D257A; APP/Ld than in wild-type or D257A mice
(Figure 7E). The p25:p35 ratio in APP/Ld mice was signifi-
cantly increased compared to wild-type mice, as observed
in other APP mice [33,34,48]. The increased p25:p35 ratio
observed in D257A; APP/Ld mice compared to APP/Ldnsgene causes morphological features of neurodegeneration.
d wild type mice were selected from similar rostral-caudal positions,
nification by light microscopy. Mouse genotypes are indicated above
ach genotype were imaged at 100× magnification. Note that D257A;
ei suggestive of marginated chromatin (e.g., black arrows). These
e bar: 50 μm).
Figure 7 (See legend on next page.)
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Figure 7 Co-expression of the PolgA D257A mutation and APP/Ld transgene causes increased levels of neurodegeneration markers, cleaved
caspase-3 and p25. 30 μg of brain homogenates from D257A; APP/Ld, D257A, APP/Ld, and wild type mice were randomly loaded and subjected to
immunoblot analysis for cleaved caspase-3 fragment and p25. Immunoblot signals were normalized to Ponceau S staining intensities in a given lane. The
numbers on immunoblot correspond to a mouse with a specific genotype as denoted in the legend key (box). (A) Full-length (f.l.) and activated cleaved
caspase-3 run at ~35 kDa and ~17 kDa respectively, as previously reported [33]. (B) Ratio of immunosignal intensities of cleaved to f.l. caspase-3. Note that
the cleaved:f.l. caspase-3 ratio is significantly increased in APP/Ld mice, although D257A; APP/Ld mice have an even greater cleaved:f.l. caspase-3 ratio,
suggesting synergism between the D257A mutation and APP/Ld transgene. (C) DAB staining using cleaved caspase-3 neoepitope antibody on coronal
sections (30 μm) demonstrate cleaved caspase-3-positive puncta in cell bodies of cortical neurons (cortical layers V and VI) of APP/Ld and D257A; APP/
Ld mice (black arrows; scale bar: 100 μm). No immunoreactivity for cleaved caspase-3 is observed in wild-type and D257A mice. (D) Immunoblots using
an antibody that recognizes both p35 and the neurodegeneration marker, calpain-cleaved p25 fragment. (E) Ratio of immunosignal intensities of p25
to p35. Note that the p25:p35 ratio is significantly elevated in APP/Ld and D257A; APP/Ld mice compared to wild-type mice. Increased p25:p35 ratio is
seen in D257A; APP/Ld compared to APP/Ld mice suggesting synergism, although this trend did not reach statistical significance. D257A mice do not have
an elevation of p25:p35 ratio (mean ± SEM; n.s. = not significant; *p < 0.05; **p < 0.01; One-way ANOVA followed by Newman–Keuls multiple-comparisons
post hoc test).
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roborated the observed neurodegeneration in D257A;
APP/Ld mice.
The brain atrophy, vacuolated neurons, caspase-3 acti-
vation, and increased p25 levels in D257A; APP/Ld mice
suggested that the bigenics might have neuron loss
compared to the other genotypes. To investigate this
possibility, we performed neuron counting in middle
layers of dorsal cortex in hematoxylin stained coronal
brain sections from the same relative rostral-caudal posi-
tions for the four genotypes of mice (Figure 8). Neuron
density was determined in regions that included vacuolated
neurons and significant cortical atrophy in the D257A;
APP/Ld mice (Figure 5A,B). Remarkably, we did not ob-
serve significant differences in neuron densities between
any of the genotypes. In retrospect, perhaps this is not sur-
prising, given that few APP transgenic mouse models ex-
hibit significant neuron death, while most do show signs of
neurodegeneration such as synaptic loss, caspase-3 activa-
tion, and increased p25. Taken together, our results suggest
that synergism between the Polg A D257A mutation and
the APP/Ld transgene in D257A; APP/Ld mice results in
enhanced neurodegeneration in the absence of frank
neuron loss.Figure 8 Co-expression of the PolgA D257A mutation and APP/
Ld transgene does not cause frank neuron loss. Representative
coronal sections (30 μm) of brains from D257A; APP/Ld, D257A, APP/Ld,
and wild type mice were selected from similar rostral-caudal positions,
stained with hematoxylin, and images centering on cortical layer V were
obtained at 100× magnification by light microscopy. Neuron density
(number of neurons per mm2) was determined by counting the number
of neurons in representative 100× fields of middle layers of dorsal cortex
for the four genotypes of mice. Note that no significant differences in
neuron densities were observed between the different genotypes (n = 5
mice/genotype; mean ± SEM; One-way ANOVA test followed by
Newman–Keuls multiple-comparisons post hoc test).Discussion
Age is the primary risk factor for AD, yet the mechanism
responsible for this association remains enigmatic. Re-
duced mitochondrial function is hypothesized to occur
during aging and in AD (reviewed in [5]) and may result
from age-associated accumulation of point mutations
and deletions in mtDNA (reviewed in [49]). Neuronal
populations are potentially more vulnerable to mito-
chondrial dysfunction due to their high bioenergetic
demands, thus providing a possible mechanistic link be-
tween aging, mitochondrial dysfunction and AD.
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plays an early part in AD pathogenesis, the precise
mechanism of Aβ neurotoxicity remains elusive. Several
APP transgenic mouse models of AD successfully recap-
itulate key features of the disease such as amyloid plaque
pathology, but fail in other aspects such as neurodegen-
eration (reviewed in [50]). Interestingly, intracerebral in-
jection of fibrillar Aβ in aged but not young primates
resulted in neuronal loss, suggesting that Aβ neurotox-
icity is a pathological response of the aging brain [51]. In
our study, we employed mitochondrial DNA mutator
PolgA D257A mice that accumulate mtDNA mutations
with age to test the hypothesis that age-related mitochon-
drial dysfunction can exacerbate amyloid pathology and
induce neurodegeneration in APP transgenic mice.
A major finding in our study was that both Aβ42
levels and amyloid plaque load were increased in the
brains of D257A; APP/Ld mice when normalized to
transgenic APP/Ld protein levels. Therefore, the D257A
mutation exacerbated the cerebral accumulation of Aβ42
per given amount of APP in the bigenic mice. Although
trends toward increased absolute Aβ42 levels and amyloid
plaque density were observed in the bigenic mice, they be-
came statistically significant when normalized to transgenic
APP/Ld levels (Figures 1 and 2). Our immunoblot analysis
for human APP revealed that there was close to 40% reduc-
tion in APP/Ld protein levels in D257A; APP/Ld bigenic
mice compared to the parental APP/Ld monogenic mice.
In contrast, endogenous mouse APP levels were unaffected
in D257A monogenic mice, demonstrating that the PolgA
mutation alone does not alter APP expression levels. We
speculate that the reduced levels of APP/Ld protein in
brains of bigenic mice might relate to neurodegenera-
tive processes that were occurring prior to neuron
death. Bigenic neurons appeared to be in a severe state
of degeneration (Figure 6) and showed caspase-3 acti-
vation and increased p25 levels (Figure 7). Given their
state of pathology, degenerating D257A; APP/Ld neu-
rons subject to Aβ neurotoxicity could well have re-
duced APP/Ld transgene transcription or translation.
Alternatively, APP/Ld in D257A; APP/Ld mice could
have undergone cleavage by increased levels of activated
caspase-3 [52], thus lowering total APP/Ld levels. Future
studies will be necessary to clarify the mechanism of de-
creased APP/Ld levels in D257A; APP/Ld bigenic brains.
The exacerbated cerebral accumulation of Aβ in D257A;
APP/Ld mice could have resulted from either increased
production or decreased clearance/degradation of Aβ.
Because we did not observe any changes in the levels of
BACE1, PS1, C99, and C83 in D257A; APP/Ld bigenic
versus APP/Ld mice (Figure 3), all evidence supporting in-
creased Aβ production in the brains of the bigenic mice is
lacking. It should be noted that BACE1 levels were signifi-
cantly increased in the brains of D257A; APP/Ld and APP/Ld compared to D257A and wild-type mice, consistent with
our previous work showing that BACE1 levels are elevated
by amyloid pathology in human AD and APP transgenic
mouse brains [32,33,53]. Nevertheless, the lack of support
for a D257A-associated increase in Aβ production sug-
gested that impaired Aβ clearance/degradation might have
led to the increase of Aβ accumulation in D257A; APP/Ld
brain. To test this hypothesis, we analyzed cerebral levels of
two major Aβ degrading enzymes, IDE and NEP. Consist-
ent with findings from other APP transgenic mice [38,39],
levels of IDE, but not NEP, were increased in response to
Aβ accumulation in the brains of APP/Ld mice (Figure 4).
This Aβ-induced increased IDE level might reflect a feed-
back mechanism that attempts to counteract the build-up
of Aβ in the brain. Additionally, IDE strongly prefers to
localize within GFAP-positive astrocytes surrounding Aβ
plaques [39]. Most importantly, in the D257A; APP/Ld
bigenic mice, we observed that the D257A mutation com-
pletely abrogated the Aβ-induced increase in IDE level.
Our study is the first to show in vivo that mitochondrial
dysfunction, by the D257A mutation, can prevent the Aβ-
induced IDE increase. Interestingly, a previous report indi-
cated that the D257A mutation can affect metabolism by
changing levels of major hormones such as leptin and
ghrelin [54]. Therefore, it is not unprecedented that the
D257A mutation can affect enzymes in metabolic pathways,
like IDE. Additionally, D257A; APP/Ld mice phenotypically
mimic aspects of advanced aging and increased mortality at
time of analysis at 12 months of age. Thus, the abrogated
IDE increase in these mice might represent an aging-
related effect [55]. Because Aβ peptide levels have been
shown to correlate inversely with IDE levels in vivo [37,56],
the blocked Aβ-induced IDE increase could be responsible
for the exacerbated amyloid accumulation in the bigenic
mice.
Previous studies of APP/Ld transgenic mice show ab-
sence of substantial brain atrophy [24,57], implying
that Aβ accumulation on its own does not cause sig-
nificant neurodegeneration. Indeed, our study supports
a two-hit hypothesis whereby Aβ is insufficient to cause
substantial neurodegeneration by amyloid buildup alone.
An additional stress factor, such as mitochondrial dysfunc-
tion, is proposed to combine with Aβ to trigger the antici-
pated cascade of events leading to neurodegeneration.
A growing body of work from two independent knockin
mouse lines has demonstrated that the PolgA D257A muta-
tion causes increased accumulation of mtDNA mutations
that leads to progressive mitochondrial dysfunction with
age [18,21,22,58-63]. Our work suggests the possibility that
Aβ toxicity might exacerbate mitochondrial dysfunction
associated with the D257A mutation, thus causing brain at-
rophy. Future studies should be undertaken to investigate
whether Aβ can worsen pre-existing age-related mitochon-
drial deficits and their effects on neurodegeneration.
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that only the bigenic D257A; APP/Ld mice exhibited a
smaller overall brain size with shrinkage of the cortex and
hippocampus, compared to the other genotypes (Figure 5).
Additionally, cortical neurons in the bigenic mice revealed
abnormal nuclear morphologies reminiscent of neurons
undergoing apoptosis [40,64]. In contrast, cortical neurons
of D257A and APP/Ld mice appeared morphologically
similar to those of wild-type mice. A time-course study
examining morphological changes in the brains of D257A;
APP/Ld compared to the other genotypes will be important
for determining when these abnormalities appear.
We also observed that the D257A; APP/Ld mice bigenic
mice exhibited significantly increased levels of activated
caspase-3 17 kDa fragment compared to the other geno-
types (Figure 7). Activated caspase-3 levels were also in-
creased in APP/Ld mice, but were less elevated compared
to the bigenic mice. We corroborated our biochemical ana-
lysis with immunohistochemical staining of brain sections
that revealed activated caspase-3-positive puncta in layer
V/VI cortex in D257A; APP/Ld and APP/Ld mouse brains.
Interestingly, in D257A mice post-mitotic tissues such as
the brain have been shown to be more resistant to the in-
duction of apoptosis by mtDNA mutations [18]. However,
the bigenic mice carrying the D257A mutation appeared to
have reduced resistance to apoptosis. These results are sig-
nificant because activated caspase-3 immunoreactivity has
been observed in AD brain [42] and in other APP trans-
genic mouse models [43,65]. Although the underlying
mechanism of brain atrophy in the D257A; APP/Ld mice is
not known, it might involve Aβ42-induced mitochondrial
cytochrome c release and subsequent activation of caspase-
3 to trigger apoptosis [66]. Importantly, significant activa-
tion of caspase-3 can lead to eventual neuron loss (reviewed
in [40,67,68]). Additionally, the levels of p25, a marker of
neurodegeneration, were the highest in bigenic mice com-
pared to the other genotypes (Figure 7).
Although we did not observe frank neuron loss in
D257A; APP/Ld mice by cell counting (Figure 8), we sus-
pect that neurons were in the process of dying, given the
brain atrophy, vacuolated neurons, activated caspase-3, and
elevated p25 levels of the bigenic mice. PolgA D257A
knockin mice do not live long past one year [18], and we
observed a dramatic increase in mortality of D257A; APP/
Ld mice at that age. Therefore, we speculate that we would
have observed frank neuron loss in the bigenic mice had
they been able to live longer. We hypothesize that the ob-
served brain atrophy and increased markers of neurodegen-
eration are primarily the result of axon and dendrite
degeneration, synaptic loss, white matter loss, or a combin-
ation of these factors, which precede neuron death.
Finally, oligomeric forms of Aβ are widely thought to
underlie important aspects of synaptic dysfunction and
neurodegeneration in AD (reviewed in [69]). Althoughwe did not examine Aβ oligomers in the current study,
the possibility exists that the D257A mutation might
affect the proportion or toxicity of Aβ oligomers in the
brains of D257A; APP/Ld bigenic mice. It will be im-
portant to conduct future studies to address the poten-
tial influence of the D257A mutation on Aβ oligomer
level, form, and neurotoxicity.
Conclusions
Taken together, the cortical thinning, reduction of hippo-
campal area, aberrant neuronal morphology, and increased
activated caspase-3 and p25 all suggest that neurodegenera-
tion in the absence of frank neuron loss is likely to be the
underlying cause of brain atrophy of the D257A; APP/Ld
mice. Moreover, this neurodegenerative phenotype appears
to have resulted from synergism between Aβ neurotoxicity
and mitochondrial dysfunction leading to reduced Aβ-
associated IDE induction, increased Aβ accumulation, and
ultimately brain atrophy. Our results support a role for age-
dependent mitochondrial dysfunction in AD pathogenesis.
Methods
Mice
APPV717I (APP/Ld) mice were generated and character-
ized previously [24]. These mice were crossbred to the
PolgAD257A/D257A mitochondrial DNA mutator mice [18].
At 12 months of age, the mice were deeply anesthetized
with ketamine/xylazine and transcardially perfused with
PBS containing protease (Cocktail Set III, Animal-free,
Cat#: 535140, Calbiochem) and phosphatase (Halt Phos-
phatase Cocktail Prod#: 1861277 Thermo Scientific) inhibi-
tors. Brains were excised and one hemibrain was drop fixed
in 4% PFA and cryopreserved in 30% sucrose, PBS for im-
munohistochemistry, while the other hemibrain was flash
frozen in liquid nitrogen for biochemical analysis. All mice
were maintained in microisolator cages in the Barrier Facil-
ities of Northwestern University Center for Comparative
Medicine. All animal procedures were in strict accordance
with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and were Northwestern
University Animal Care and Use Committee approved.
Tissue preparation for biochemical analysis
Hemibrains were flash frozen in liquid N2 and stored
at -80°C. Frozen mouse hemibrains were homogenized
in 1× PBS, 1% Triton X-100, 1× protease inhibitor cocktail
(Calbiochem), and 1× Halt phosphatase inhibitor cocktail
(Thermo Scientific). Total protein concentration was deter-
mined by the BCA method (Pierce).
Human Aβ42 ELISA
Total Aβ42 levels in brain homogenates were deter-
mined using a human Aβ (1-42) ELISA kit (Wako Pure
Chemical Industries, Ltd.), according to manufacturer’s
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brain homogenates (~1 mg total protein) was extracted for
four hours in 5 M guanidine-HCl at room temperature
(300 μl total volume). Homogenates were further diluted
10-fold in ice-cold casein buffer (0.25% casein/0.05% so-
dium azide/5 mmol/l EDTA, pH 8.0 in PBS with 1× prote-
ase inhibitor cocktail (Calbiochem), centrifuged at 16,000 g
for 20 min at 4°C, and then diluted again 1:50 with Stand-
ard diluent. Samples were run in duplicates on Aβ42-
specific ELISA (100 μl/well). Optical densities (450 nm) of
each well were read on a Spectra Max 250 plate reader
(Molecular Devices Corp., Sunnyvale, CA), and sample
Aβ42 concentrations were determined by comparison with
the Aβ42 standard curves. Each reading was conducted in
the linear range of the assay. Aβ42 concentration values
were normalized to total brain protein concentrations and
were expressed as nanograms of Aβ42 per milligram total
protein, and the average of the duplicates was defined as
the Aβ42 concentration for a given mouse.
In order to normalize Aβ42 concentration to APP
transgenic protein level for each mouse, the Aβ42 con-
centration was divided by a normalization factor (NF)
calculated for a given mouse. To do so, immunoblots
were performed on mouse brain homogenates to meas-
ure full-length human APP levels using the 6E10 anti-
body (see Immunoblotting Section). Following enhanced
chemiluminescence detection, the raw sum intensities of
APP immunoblot band signals for all mice were deter-
mined and normalized to Ponceau S staining. Next, the
mean of the normalized APP immunoblot signal inten-
sities for the APP/Ld mice as a group was determined.
The APP immunoblot signal intensity for each APP/Ld
and D257A; APP/Ld mouse was then divided by the
APP/Ld mean intensity to derive an individual NF for
every mouse. Finally, a given Aβ42 ng/mg total protein
ELISA value was divided by the individual NF for each
mouse to calculate the mouse’s Aβ42 concentration nor-
malized to APP transgenic protein level, and then means
and SEMs for each genotype were determined.
Immunoblotting
In general, 10-30 μg protein from whole-brain homoge-
nates were heated at 95°C in sample boiling buffer (60 mM
Tris HCl, 5% SDS, 10% glycerol, pH = 6.8) with 5× loading
dye (90% BME, 10% of 5% Bromophenol blue dye) before
SDS-PAGE separation on 4%–12% NuPAGE Bis-Tris gels
in 1× MES or MOPS running buffer (Invitrogen, Carlsbad,
CA). Alternatively, samples for PS1-NTF immunoblot were
not boiled but were otherwise prepared similarly. For C99
and C83 immunoblots, samples were separated on 16%
Tris-glycine gels using 1× Tris-glycine as a cathode buffer
and 200 mM Tris-base (pH 8.8) as an anode buffer. Pro-
teins were electrophoretically transferred onto Millipore
Immobilon-P polyvinylidene difluoride (PVDF) membrane(Millipore, Billerica, MA). Multiple protein gels were run
in parallel to accommodate the large number of samples.
When conducting the protein transfer step, gels were
aligned horizontally and transferred onto a single piece of
PVDF membrane. This process ensured consistency as all
samples then were developed on the same PVDF mem-
brane. After completing protein transfer, PVDF membranes
were stained with Ponceau S and imaged on a scanner.
Blots were then blocked in 5% non-fat dry milk in
Tris-buffered saline (TBS), 0.1% Tween 20 (TBST;
Sigma) for 1 h at room temperature, then incubated in
primary antibody (human APP: Aβ Mouse mAb 6E10,
Chemicon Cat. # MAB1560, 1:1,000; human and mouse
APP: Anti-Alzheimer Precursor Protein A4 Mouse mAb
N-term specific, 22C11, Millipore Cat. # MAB348SP OR
Rabbit mAb APP C-terminus, Y188, Epitomics Cat. #
1565-1, 1:5000; BACE1: Mouse mAb, 3D5 [32], 1:1000;
C99 and C83: Rabbit mAb APP C-terminus, Y188,
Epitomics Cat. # 1565-1, 1:5000; PS1: α-PS1NTF Rabbit
pAb, a generous gift from Dr. Gopal Thinakaran (U.
Chicago), 1:5000; Insulin Degrading Enzyme: α-IDE
Rabbit pAb, Abcam Cat. # ab32216, 1:1000; Neprilysin:
Anti-CD10 Rabbit mAb, EPR2997, Abcam Cat. # ab79423,
1:1000; Cleaved Caspase-3: Rabbit mAb, 5A1E, Cell Signal-
ing Cat. # 9664, 1:1000; Caspase-3 (full-length): Rabbit
pAb, Cell Signaling Cat. # 9662, 1:1000; p25 and p35:
Rabbit pAb, C-19, Santa Cruz Biotechnology Cat. # sc-820,
1:1000) for 2 hrs at RT or overnight at 4°C. Blots were
washed in TBST and incubated for 1 h in horseradish per-
oxidase (HRP)-conjugated goat anti rabbit (Jackson Immu-
noResearch Laboratories, West Grove, PA) or horse anti-
mouse (Vector Laboratories) secondary antibodies diluted
1:10,000 in 5% milk in TBST. Immunosignals were detected
using enhanced chemiluminescence (EMD Millipore
Luminata Classico, Crescendo, or Forte) and quantified
using a Kodak Image Station 4000R imager (Rochester,
NY). Densitometric analyses of immunoblots and im-
ages of Ponceau S-stained blots were performed using
Kodak Molecular Imaging Software SE. Immunosignals
were normalized to the measured intensity of whole
lane Ponceau S staining. Values were expressed as per-
centages of the mean of the control.Immunofluorescence microscopy of tissue sections
Coronal sections of 30 μm were cut on a freezing sliding
microtome and were selected with equivalent rostral-caudal
locations using anatomical landmarks and the size and
shape of the hippocampus and ventricles. Free-floating
sections were washed 3× (10 min each) in TBS + 0.25%
Triton-× 100 (TBS +T) and blocked for 90 min in 5% goat
serum with TBS +T. Then they were washed 2× (10 min
each) in 1% BSA with TBS +T before being incubated in
anti-Aβ42 C-terminus specific rabbit polyclonal antibody
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night on an orbital shaker.
The sections were washed again the next day 2× (each
10 min) in 1% BSA with TBS + T before being incubated
in secondary antibody solution of Alexa-Fluor Donkey
anti rabbit-488 (A21206 along with DAPI (300nM) and
thiazine red (1:60 k). Sections were washed in TBS in a dark
room before mounting with ProLong gold antifade reagent
(Life Technologies #P36934) and coverslipping #1.5
(VWR). Sections were imaged with a 10× air objective
of a Keyence BZ-9000 Series microscope. Images were
stitched using Keyence proprietary software. High magnifi-
cation images of plaques were acquired on UV LSM510
laser scanning confocal microscope using laser lines of
405 nm (blue) 488 nm (green) and 561 nm (red).
Amyloid plaque density
The total number of Aβ42-positive plaques was counted
manually from one coronal section per mouse taken
from the same mid-rostral-caudal location in the brain.
10-12 mice of each genotype (APP/Ld monogenic or
D257A; APP/Ld bigenic) were used for plaque counting.
The plaque density was then determined by dividing the
total number of Aβ42-positive plaques by the total area
of the section analyzed per mouse. The mean number of
Aβ42-positive plaques per cm2 was then calculated for a
given genotype. Additionally, mean plaque density was
normalized to transgenic human APP protein level by
dividing the plaque density of each mouse by that mouse’s
respective NF value (see Human Aβ42 ELISA methods).
SEMs and p-values were determined using the two-tailed
Student’s t-test.
Histology and related measurements
Coronal sections with equivalent mid-rostral-caudal lo-
cations in the brain were selected for histological stain-
ing and all related measurements. Hematoxylin staining
was performed according to the manufacturer’s protocol
(Vector Labs). Sections were dried on Superfrost Plus
micro glass slides (VWR) for ~10 minutes to facilitate
adhesion. Once stuck to the slide, the sections were then
rehydrated with a few drops of water. The sections were
then stained with Vector Hematoxylin QS for about
1 minute, and then rinsed with tap water until water
washed over the sections was colorless. Afterward, sections
were dehydrated in a series of alcohols (70%, 95%, 95%,
100%, and 100%), cleared in xylene, and coverslipped with
Permount mounting medium (Fisher Scientific, SP15).
On hematoxylin stained sections, lateral cortical thick-
ness was measured by the length of a line running per-
pendicular to the cortical layers connected from the tip
of the CA1 region to the visible boundary of the cortex.
Higher magnification images of the cortex stained with
hematoxylin was acquired on Leica M165 FC or ZeissAxioskop/CRi Nuance camera microscopes. Using images
acquired on a Nikon Eclipse E800 microscope, the hippo-
campal area was measured by drawing a freehand selection
around the hippocampus in ImageJ software (NIH).
Neuron density (number of neurons per mm2) was de-
termined by counting the number of neurons in middle
layers of the dorsal cortex in 30 μm thick hematoxylin
stained coronal brain sections. Three sections spaced 15
sections apart that had the same relative rostral-caudal
positions (centered over the mid-hippocampus; Figure 5A)
in each mouse were chosen and two representative fields
per section were counted using a Zeiss Axioskop micro-
scope with a 100× oil objective in bright-field. All neurons
(as identified by their large round nuclei) were counted in
each 100× field, while glial cells (as identified by their
small dense nuclei) were not counted. A total of 5 mice
per genotype were counted and the mean neuron num-
ber per genotype was determined and converted to
neuron density.
The Vector Laboratories (Burlingame, CA) ABC kit
was used with DAB as chromogen to visualize the reac-
tion product of cleaved caspase-3. On Day 1 of staining,
sections were first incubated in 0.4% Triton at room
temperature for 30 min. The sections were briefly rinsed
in PBS before and after each incubation step, unless
otherwise specified. The sections were subsequently in-
cubated in vehicle/Serum (0.1% Triton X-100, 3% Goat
Serum in PBS) at 4°C on shaker for 1 h. Sections were
then incubated in H2O2 (1% in PBS) at 4°C for 1 h,
followed by incubation in the primary antibody (anti-
cleaved caspase 3, Rabbit mAb, 5A1E, 1:500), diluted in
1% BSA in TBS with 0.25% Triton X-100. On Day 2, sec-
tions were incubated in secondary antibody (Vector,
Goat anti-Rabbit-HRP, 1:500) at 4°C for 2 hrs, followed
by incubation in Reagent A + B (1% of each reagent in
Vehicle solution) at 4°C for 2 hrs. The reagent solution
was made at least 30 minutes prior to use. The sections
were submerged in urea (120 mg/ml diluted in H2O)—
no shaking—then briefly rinsed 2× in PBS followed by
3× in 0.05 M TRIS. Two development solutions (0.07%
H2O2 in H2O; 1 mg/ml Diaminobenzidine in 0.05 M
TRIS) were made and then mixed just before the devel-
opment step. Sections were incubated in the development
solution from 30 sec to 5 min until sufficient degree of
color development occurred by visually inspecting the sec-
tions under a microscope. Finally, the sections were briefly
rinsed in 0.05 M TRIS, dried overnight, dehydrated in a
series of alcohols, cleared in xylene and coverslipped with
Permount mounting medium.
Statistical analysis
Data are presented as means and standard errors of the
mean (SEMs, represented by error bars in histograms).
N-values are stated in figure legends. GraphPad Prism
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all statistical analysis. The statistical significance between
means of experimental and control groups was deter-
mined using the two-tailed Student’s t-test. For compari-
sons involving more than 2 groups, one-way ANOVA
was used followed by post hoc Newman-Keuls multiple
comparison test (*p < 0.05, **p < 0.01, ***p < 0.001).
Additional file
Additional file 1: Figure S1. PolgA D257A mutation does not affect
endogenous mouse APP protein levels. (A) Brain homogenates were
prepared from D257A; APP/Ld, D257A, APP/Ld, and wild type mice and
10 μg total protein per lane was randomly loaded and subjected to
immunoblot analysis using anti-APP N-terminal antibody (22C11). Immunoblot
signals were normalized to Ponceau S staining intensities in a given lane. The
numbers on immunoblot correspond to a mouse with a specific genotype as
denoted in the legend key (box). (B) APP immunosignals in (A) were measured
and expressed as percentage of mean wild-type APP level. Note that
endogenous APP levels were not significantly different between wild-type and
D257A mice (mean ± SEM; **p < 0.01; Student’s t-test).
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